Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Madrigal Pharmaceuticals, Inc. (MDGL) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed biopharmaceutical company focused on MASH, Madrigal uses SEC reports to present detailed information on its financial performance, capital structure, risk factors, and material corporate events related to Rezdiffra (resmetirom) and its broader pipeline.
Investors can review current reports on Form 8-K where Madrigal announces quarterly and annual financial results, material financing arrangements, licensing agreements, and other significant events. Recent 8-K filings describe quarterly earnings releases, a senior secured credit facility with funds managed by Blue Owl Capital, and the use of proceeds to repay and terminate a prior loan agreement, as well as shareholder voting results from the annual meeting.
In addition to 8-Ks, users can access Madrigal’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) to study revenue from Rezdiffra, research and development spending on the MAESTRO clinical program and pipeline assets such as the licensed oral GLP-1 receptor agonist and ervogastat, and detailed risk factor disclosures. These filings also discuss regulatory considerations around MASH indications, ongoing Phase 3 outcomes trials, and forward-looking statements about the company’s strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from long filings, helping readers quickly understand changes in liquidity, debt covenants, operating expenses, and other important metrics without reading every page. Users can also track executive and director-related disclosures when Forms 3, 4, and 5 appear in the SEC stream, providing visibility into equity awards and other reportable transactions.
By combining real-time EDGAR updates with AI-generated insights, this page offers a practical way to follow how Madrigal’s clinical progress in MASH, commercialization of Rezdiffra, and financing decisions are reflected in its official SEC reporting.
Madrigal Pharmaceuticals (MDGL) reported a sharp commercial ramp for Rezdiffra as product revenue reached $287.3 million in Q3 2025, up from $62.2 million a year ago. For the nine months ended September 30, 2025, product revenue totaled $637.3 million versus $76.8 million in 2024.
The company posted a net loss of $114.2 million for Q3 and $229.7 million year-to-date, reflecting higher selling, general and administrative expenses tied to commercialization and increased R&D. Liquidity remained strong with cash, cash equivalents and marketable securities of $1.11 billion, while long‑term debt rose after funding a $350.0 million initial term loan under a new credit facility that provides up to $500.0 million in commitments and requires at least $100.0 million of unrestricted cash. Accrued liabilities include a $117.3 million CSPC license upfront expense accrued and paid in October.
Rezdiffra received European Commission approval in August 2025 and launched in Germany in September, adding an early ex‑U.S. foothold alongside U.S. sales.
Madrigal Pharmaceuticals (MDGL)
The information is furnished under Item 2.02 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly stated.
Madrigal Pharmaceuticals is registering 300,000 shares of common stock reserved for issuance under its 2025 Inducement Stock Plan, as amended. This plan is used to grant equity and other inducement awards to new hires who qualify under Nasdaq Listing Rule 5635(c)(4), rather than through a stockholder-approved plan. The Board adopted the plan on June 16, 2025 and approved an amendment on September 11, 2025 that increased the share pool by 300,000 shares. The filing also includes legal opinions, auditor consent, and plan-related award agreement forms as exhibits.
Madrigal Pharmaceuticals (MDGL) submitted a Form 144 reporting proposed and recent insider sales of common stock. The filer disclosed a proposed sale of 7,279 shares through Morgan Stanley Smith Barney with an aggregate market value of $3,303,210.20, listing Nasdaq as the exchange and an approximate sale date of 09/09/2025. The shares were acquired as a Restricted Stock Unit grant that vested on 09/08/2025 and the payment/nature of the transaction is recorded as vesting of RSUs. The filing also reports that William John Sibold sold 7,616 shares on 08/21/2025 for $3,047,756.28. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.
William John Sibold, President, CEO and a director of Madrigal Pharmaceuticals, Inc. (MDGL), reported a sale of 7,279 shares of common stock on 09/09/2025 at a reported price of $445.63 per share. The filing states the shares were sold by the issuer on the reporting person’s behalf to cover tax withholding obligations related to the vesting of restricted stock units. After the transaction, Mr. Sibold beneficially owned 102,474 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Madrigal Pharmaceuticals (MDGL) notice reports a proposed sale under Rule 144 by an affiliate who acquired 2,900 common shares on 08/29/2025 by exercising options under a registered plan and intends to sell them through Morgan Stanley Smith Barney on 08/29/2025 on NASDAQ for an aggregate market value of $1,251,895.78. The filer lists the issuer's outstanding shares as 22,289,014. The form also discloses that the same person sold 7,100 shares in three transactions during August 2025, generating total gross proceeds of approximately $2,657,186.88. The signer certifies no undisclosed material adverse information.
William J. Sibold, President, CEO and Director of Madrigal Pharmaceuticals, Inc. (MDGL), reported sales of company common stock on 08/21/2025 executed under a Rule 10b5-1 trading plan adopted on 11/15/2024. The filing shows an automated sale of 6,485 shares at a weighted-average price of $400.0347, after which the reporting person beneficially owned 110,884 shares. A subsequent automated sale of 1,131 shares at a weighted-average price of $401.0003 reduced beneficial ownership to 109,753 shares. The reporting person signed the Form 4 through an attorney-in-fact on 08/21/2025. All sales are disclosed as having been effected automatically pursuant to the specified 10b5-1 plan and the filing provides weighted-average price ranges for the transactions.
Madrigal Pharmaceuticals (MDGL) filed a Form 144 notifying the proposed sale of 7,616 common shares through Morgan Stanley Smith Barney on 08/21/2025, with an aggregate market value listed as $2,982,882.56 and 22,289,014 shares outstanding. The securities were acquired on 09/08/2024 as Restricted Stock Units from the issuer, with payment/vesting dated 09/08/2024. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Madrigal Pharmaceuticals insiders associated with Baker Bros. reported multiple purchases of Common Stock on August 18 and August 20, 2025. The filings show a series of market purchases (transaction code P) executed at weighted-average prices ranging roughly from $372.59 to $392.57 per share. The reported entries record incremental increases in indirect beneficial ownership for Baker-related reporting persons and funds, with reported position levels shown in the filing as approximately 1,947,968 shares for one reported position and about 202,813 shares for another at various post-transaction lines. Footnotes explain these holdings are indirect and arise from the reporting persons' relationships to investment funds and the adviser, and that some shares reflect vested restricted stock units previously granted to directors.
Madrigal Pharmaceuticals insiders and affiliated funds reported multiple purchases of Common Stock on 08/18/2025. The filings show aggregated acquisitions executed in multiple transactions at weighted-average prices ranging roughly from $353.76 to $372.50 per share. Following the reported purchases, the filings list two classes of beneficial ownership totals: approximately 193,000 shares and approximately 1,859,091–1,848,963 shares across different line items, reflecting purchases by 667, L.P. and Baker Brothers Life Sciences, L.P., with Baker Bros. Advisors LP as adviser. Reporting persons include Baker Bros. entities, Julian C. Baker, Felix J. Baker and directors including Dr. Raymond Cheong. The filing is noted as the first of two Form 4s covering these changes.